Evidence map›Paper›PMID 32616772›Full record

ArticleScientific reports2020

Activity of vitamin D receptor agonists against dengue virus.

Janejira Jaratsittisin, Bin Xu, Wannapa Sornjai, Zhibing Weng, Atichat Kuadkitkan, Feng Li, Guo-Chun Zhou, Duncan R Smith

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Janejira JaratsittisinInstitute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.
Bin XuSchool of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, Jiangsu, China.
Wannapa SornjaiInstitute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.
Zhibing WengSchool of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, Jiangsu, China.
Atichat KuadkitkanInstitute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand.
Feng LiSchool of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, Jiangsu, China.
Guo-Chun ZhouSchool of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, Jiangsu, China. gczhou@njtech.edu.cn.
Duncan R SmithInstitute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand. duncan_r_smith@hotmail.com.
Mahidol University · THNanjing Tech University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections with the mosquito-transmitted dengue virus (DENV) are a pressing public health problem in many parts of the world. The recently released commercial vaccine for DENV has encountered some problems, and there is still no effective drug to treat infections. Vitamin D has a well characterized role in calcium and phosphorus homeostasis, but additionally has a role in the immune response to bacterial and viral pathogens. In this study a number of fused bicyclic derivatives of 1H-pyrrolo[1,2]imidazol-1-one with vitamin D receptor (VDR) agonist activity were evaluated for possible anti-DENV activity. The results showed that five of the compounds were able to significantly inhibit DENV infection. The most effective compound, ZD-3, had an EC

Indexed as

CalcitriolCells, CulturedDengueDengue VirusHumansImidazolesImmunosuppressive AgentsReceptors, CalcitriolVirus ReplicationCalcitriolImidazolesImmunosuppressive AgentsReceptors, CalcitriolseocalcitolVDR protein, human

Identifiers

PMID32616772
PMCPMC7331731
OpenAlexW3039744401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.